| Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis (NCT04725136) | Kang Stem Biotech Co., Ltd. | 2021-01-27 |
| The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine (NCT04686955) | Taipei Veterans General Hospital, Taiwan | 2021-01-25 |
| Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis (NCT04753034) | Teres Bio, Inc. | 2021-01-18 |
| Dupilumab in Japanese Patients With Atopic Dermatitis (NCT04678882) | Sanofi | 2021-01-15 |
| Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis (NCT04706559) | B.P. Koirala Institute of Health Sciences | 2021-01-03 |
| Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects. (NCT04615962) | Seanergy Dermatology Ltd. | 2021-01-01 |
| Study of the Skin Microbiome and the Potential of a Topical Probiotic Cream for Atopic Dermatitis (NCT04771910) | University Hospital, Antwerp | 2021-01-01 |
| Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (NCT04717310) | Reistone Biopharma Company Limited | 2020-12-30 |
| Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (NCT04664153) | Pfizer | 2020-12-21 |
| Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis (NCT04668066) | Pfizer | 2020-12-10 |
| A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (NCT04693195) | Bellus Health Inc. - a GSK company | 2020-12-09 |
| Assessing SleeP IN Infants With Atopic Dermatitis by Longitudinal Evaluation (NCT05031754) | University College Cork | 2020-12-03 |
| Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis (NCT04539639) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-12-02 |
| Hand Sanitizer Effects on the Skin Barrier (NCT04525521) | National Jewish Health | 2020-12-01 |
| Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism (NCT04455906) | Boston Children's Hospital | 2020-11-30 |
| Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes (NCT04965233) | Studies&Me | 2020-11-30 |
| Blue Light in the Treatment of Inflammatory Skin Diseases (NCT06516783) | Medical University of Lodz | 2020-11-27 |
| A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis (NCT04643457) | UCB Biopharma SRL | 2020-11-27 |
| Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates (NCT04271007) | Libbs Farmacêutica LTDA | 2020-11-23 |
| A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) (NCT04626297) | Eli Lilly and Company | 2020-11-17 |
| Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients (NCT04633616) | University of Southern California | 2020-11-16 |
| Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis (NCT04605094) | AstraZeneca | 2020-11-12 |
| Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (NCT04587453) | LEO Pharma | 2020-10-27 |
| Skin Barrier Abnormalities and Oxidative Stress Response (NCT04606615) | National Jewish Health | 2020-10-16 |
| Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum (NCT04274348) | Poitiers University Hospital | 2020-10-15 |
| Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis (NCT04283968) | Tel-Aviv Sourasky Medical Center | 2020-10-15 |
| Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis (NCT05644691) | Cosmetique Active International | 2020-10-14 |
| Jaktinib Hydrochloride Cream For Atopic Dermatitis (NCT04435392) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-14 |
| A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis (NCT04737304) | BenevolentAI Bio | 2020-10-14 |
| Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis (NCT04504279) | Forte Biosciences, Inc. | 2020-10-13 |
| Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study (NCT05276323) | Soroka University Medical Center | 2020-10-01 |
| Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone (NCT04154033) | University of Minnesota | 2020-10-01 |
| The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata (NCT04239521) | Momentum Data | 2020-10-01 |
| Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis (NCT04598269) | Aclaris Therapeutics, Inc. | 2020-09-30 |
| A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis (NCT04498403) | Pfizer | 2020-09-14 |
| The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment (NCT04358224) | Jonathan A. Bernstein, MD | 2020-09-01 |
| An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis (NCT04520308) | Eric Simpson | 2020-09-01 |
| Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema (NCT04486742) | Northwestern University | 2020-09-01 |
| A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon) (NCT04530643) | Shaperon | 2020-08-26 |
| Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis (NCT04728269) | PiLeJe | 2020-08-19 |
| Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis (NCT04360187) | Pfizer | 2020-07-27 |
| Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood (NCT04398758) | Infectopharm Arzneimittel GmbH | 2020-07-22 |
| Dupilumab Skin Barrier Function Study in Atopic Dermatitis (NCT04447417) | Sanofi | 2020-07-16 |
| CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness (NCT04504955) | CorEvitas | 2020-07-14 |
| B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis (NCT04490109) | AOBiome LLC | 2020-06-24 |
| Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (NCT04392154) | Eli Lilly and Company | 2020-06-15 |
| National Register of Moderate and Severe Adult Atopic Dermatitis (NCT06313333) | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse | 2020-06-15 |
| A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis (NCT04256174) | Akesobio Australia Pty Ltd | 2020-06-15 |
| Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (NCT04345367) | Pfizer | 2020-06-11 |
| Comprehending Atopic Risk Elements (NCT04325451) | MYOR Ltd. | 2020-06-03 |
| A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients (NCT04369846) | Xantho Biotechnology Co., LTD | 2020-05-04 |
| A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients (NCT04352595) | Tianjin Hemay Pharmaceutical Co., Ltd | 2020-04-24 |
| The Effectiveness of Antibacterial Therapeutic Clothing Based on Silver or Chitosan as Compared With Non-antibacterial Therapeutic Clothing in Patients With Moderate to Severe Atopic Dermatitis (NCT04297215) | Erasmus Medical Center | 2020-03-17 |
| Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis (NCT04313400) | Amytrx Therapeutics, Inc. | 2020-03-10 |
| The Factors Affecting Atopic Dermatitis in Children Age 1-3 (NCT04218877) | Akusherstvo Pro | 2020-03-10 |
| Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis (NCT04413942) | Oneness Biotech Co., Ltd. | 2020-03-10 |
| Dupilumab Impact on Skin Resident Memory T Cells (NCT03983460) | Association pour la Recherche Clinique et Immunologique | 2020-03-09 |
| A First-in-Human Study of CEE321 in Adult Subjects (NCT04612062) | Novartis Pharmaceuticals | 2020-02-27 |
| Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment (NCT04276623) | UMC Utrecht | 2020-02-25 |
| A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD) (NCT04262791) | AbbVie | 2020-02-17 |
| Topical L. Reuteri in Children With Atopic Dermatitis (NCT04265716) | Innovacion y Desarrollo de Estrategias en Salud | 2020-02-13 |
| Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (NCT04250350) | Eli Lilly and Company | 2020-02-11 |
| Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis (NCT05059509) | Oneness Biotech Co., Ltd. | 2020-02-06 |
| Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis (NCT04214197) | Massachusetts General Hospital | 2020-02-03 |
| Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (NCT04250337) | Eli Lilly and Company | 2020-02-03 |
| Stress-induced Scratching in Healthy and AD (NCT04174651) | University of Miami | 2020-01-27 |
| Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT04195698) | AbbVie | 2020-01-15 |
| Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata (NCT03976622) | University Hospital, Bordeaux | 2020-01-14 |
| Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (NCT04211415) | Daiichi Sankyo Co., Ltd. | 2020-01-13 |
| Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age (NCT03684343) | University Hospital, Brest | 2020-01-13 |
| Skin Tape Transcriptome Methods in Children (NCT04180644) | National Jewish Health | 2020-01-10 |
| Vitamin D and Its Receptor Gene Polymorphisms in Lithuanian, Latvian and Taiwanese Patients With Atopic Dermatitis and Asthma (NCT04354207) | Lithuanian University of Health Sciences | 2020-01-01 |
| Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis (NCT05765461) | Cosmetique Active International | 2019-12-31 |
| Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis (NCT04307862) | Shulov Innovate for Science Ltd. 2012 | 2019-12-29 |
| Steroid-reducing Effects of Crisaborole (NCT03832010) | Johns Hopkins University | 2019-12-17 |
| Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis (NCT04137562) | EHL Bio Co., Ltd. | 2019-12-11 |
| Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (NCT04212169) | AstraZeneca | 2019-12-09 |
| Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab (NCT04066998) | Centre Hospitalier Universitaire de Besancon | 2019-12-01 |
| Hydration Sensor for Atopic Dermatitis (NCT03813472) | Northwestern University | 2019-11-25 |
| Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis (NCT04553224) | Pierre Fabre Dermo Cosmetique | 2019-11-12 |
| Pre-SunBeam TEWL AUC (NCT04226092) | Northwestern University | 2019-11-07 |
| A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT04162899) | Reistone Biopharma Company Limited | 2019-11-06 |
| Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (NCT04178967) | Eli Lilly and Company | 2019-10-29 |
| Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD (NCT04339985) | UNION therapeutics | 2019-10-22 |
| Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) (NCT04140695) | Vanda Pharmaceuticals | 2019-10-21 |
| A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis (NCT04021862) | Janssen Research & Development, LLC | 2019-10-16 |
| A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT04162769) | Arena Pharmaceuticals | 2019-10-04 |
| Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (NCT04023084) | Ann & Robert H Lurie Children's Hospital of Chicago | 2019-10-03 |
| Microbiome in Atopic Dermatitis Under Systemic Therapy (NCT05099315) | Charite University, Berlin, Germany | 2019-10-01 |
| Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation (NCT05098821) | Charite University, Berlin, Germany | 2019-10-01 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) (NCT03936335) | Regeneron Pharmaceuticals | 2019-09-30 |
| Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) (NCT04146363) | Eli Lilly and Company | 2019-09-24 |
| Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT03817190) | DS Biopharma | 2019-09-19 |
| Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period (NCT04008784) | Clinical Research Center of the Carolinas | 2019-09-16 |
| A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis (NCT04040192) | Pfizer | 2019-09-12 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis (NCT04090229) | ASLAN Pharmaceuticals | 2019-09-09 |
| Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis (NCT03847389) | Hill Dermaceuticals, Inc. | 2019-09-09 |
| Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients (NCT04087863) | Kang Stem Biotech Co., Ltd. | 2019-08-29 |
| Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis (NCT03981926) | University of Southern California | 2019-08-27 |
| The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover (NCT04114097) | Jacob Thyssen | 2019-08-22 |